MannKind (MNKD) Q2 2026 earnings summary

Executive summary

• Achieved three major 2026 catalysts: Afrezza pediatric approval and launch, FUROSCIX ReadyFlow FDA approval, and positive Phase 1b nintedanib DPI results in IPF patients, with commercial product revenues now outpacing royalties as the primary growth driver.

• Q2 2026 total revenues reached $109.4M, up 43% year-over-year, driven by strong Afrezza pediatric launch and FUROSCIX performance, with commercial product revenues growing 27% sequentially.

• Diversification strategy succeeded as marketed products overtook royalties as the top revenue source for the first time.

• The company completed the acquisition of scPharma in October 2025, adding FUROSCIX and ReadyFlow to its portfolio.

Financial highlights

• Q2 2026 revenue reached $109.4M, up 43% year-over-year; first half revenue $199.5M, up 29%.

• FUROSCIX net sales were $22.2M, up 43% sequentially; Afrezza net sales $17.0M; royalties from United Therapeutics $32.4M (+4% YoY); collaborations/services revenue $35M (+53%).

• Commercial product sales rose 87% YoY to $42.0M in Q2, mainly from FUROSCIX.

• GAAP net loss of $19M vs. net income of $0.7M prior year; non-GAAP net loss of $2.7M vs. net income of $13.9M.

• Gross margin on commercial products fell to 66% in Q2 2026 from 79% in Q2 2025, reflecting the lower margin profile of FUROSCIX.

Outlook and guidance

• FUROSCIX 2026 revenue guidance of $110M–$120M, with expected back-half weighting due to payer dynamics and product launch timing.

• ReadyFlow launch and pediatric Afrezza expected to accelerate growth and margin improvement into 2027.

• Continued investment in launches and pipeline, with focus on execution and cost discipline; IND filing for ralinepag DPI on track for year-end 2026.

• Management expects continued revenue growth from FUROSCIX and Tyvaso DPI, with additional upside from new product launches and expanded indications.

• The company believes current liquidity and revenue streams will support operations for at least the next 12 months.